Potassium Phosphates INJECTION is contraindicated in patients with: Intravenous administration of Potassium Phosphates to correct hypophosphatemia in single doses of phosphorus 50 mmol and greater and/or at rapid infusion rates (over 1 to 3 hours) in intravenous fluids has resulted in death, cardiac arrest, cardiac arrhythmia (including QT prolongation), hyperkalemia, hyperphosphatemia, and seizures [see Overdosage (10)]. Parenteral nutrition solutions with an osmolarity of 900 mOsm/L or greater must be infused through a central catheter [see Dosage and Administration (2.3)]. Tripotassium phosphate. The formula for potassium phosphate is K3PO4. Thus, it takes 3 K's for each PO4. Calcium and phosphate ratios must be considered. Serum phosphorus is believed to be filterable by the renal glomeruli and the major portion of filtered phosphorus (greater than 80%) is actively reabsorbed by the tubules. Risk Summary The following clinically significant adverse reactions are described elsewhere in the labeling: The following adverse reactions in Table 3 have been reported in clinical studies or postmarketing reports in patients receiving intravenously administered Potassium Phosphates. A deficiency in potassium phosphate could cause several health issues Any storage of the admixture should be under refrigeration from 2°C to 8°C (36°F to 46°F) and limited to a brief period of time, no longer than 24 hours. Concurrent use with phosphate may cause or worsen renal damage. Hyperphosphatemia leads in turn to hypocalcemia, which may be severe, and to ectopic calcification, particularly in patients with initial hypercalcemia. (H 2 O) x (x = 0, 3, 7, 9). Potassium Phosphates INJECTION is for intravenous infusion only after dilution or admixing. Preterm infants are particularly at risk for aluminum toxicity because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which also contain aluminum. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Inform patients, caregivers or home healthcare providers of the following risks of Potassium Phosphates INJECTION: Distributed by: For further information about unapproved drugs, click here.----- Patients with renal impairment, including preterm infants, who receive greater than 4 to 5 mcg/kg/day of parenteral aluminum can accumulate aluminum to levels associated with central nervous system and bone toxicity. Potassium Phosphate Formula. Potassium Phosphates INJECTION provides phosphorus 3 mmol/mL (potassium 4.7 mEq/mL). Avoid use of Potassium Phosphates INJECTION in patients receiving such products. The maximum initial or single dose of phosphorus is 45 mmol (potassium 71 mEq) [see Warnings and Precautions (5.1)]. Visually inspect the solution for particulate matter and discoloration before and after dilution and prior to administration. Select one or more newsletters to continue. Exposure to aluminum from Potassium Phosphates INJECTION is not more than 4.9 mcg/kg/day when: When prescribing Potassium Phosphates INJECTION for use in parenteral nutrition solutions containing other small volume parenteral products, the total daily patient exposure to aluminium from the admixture should be considered and maintained at no more than 5 mcg/kg/day [see Use in Specific Populations (8.4)]. Store at 2°C to 8°C (36°F to 46°F). Individualize the dosage based upon the patient’s clinical condition, nutritional requirements, and the contribution of oral or enteral phosphorus and potassium intake. Festival of Sacrifice: The Past and Present of the Islamic Holiday of Eid al-Adha. Interaction with Diuretics or Thiazides. The mineral is contained in high-protein foods, whole grains and dried fruit. Structure: Find Similar Structures. When administering Potassium Phosphates INJECTION in intravenous fluids to correct hypophosphatemia, check the serum potassium concentration prior to administration. Potassium Phosphates INJECTION, USP, is a phosphorus replacement product containing phosphorus 45 mmol/15 mL (3 mmol/mL) and potassium 71 mEq/15 mL (4.7 mEq/mL). 3H 2 O. Molecular Weight: 228.22. Tissue calcification may cause hypotension and organ damage and result in acute renal failure. Protect the parenteral nutrition solution from light during storage. 1.19754 ; ... Potassium Phosphate Monobasic solution, Potassium dihydrogen phosphate solution CAS Number: 7778-77-0. Most individuals, however, are able to obtain an ample amount of phosphorous from their normal diet. Do not administer unless solution is clear, and seal on the vial is intact. Potassium Phosphates INJECTION is indicated as a source of phosphorus for parenteral nutrition in adults weighing at least 45 kg and pediatric patients 12 years of age and older weighing at least 40 kg when oral or enteral nutrition is not possible, insufficient or contraindicated. CAS Number: 16788-57-1. Limitations of Use The concentration of the diluted solution should take into consideration the amounts of phosphorus and potassium to be administered and is dependent upon whether administration will be through a peripheral or central venous catheter. Potassium is K (with a 1+ valence) and the phosphate anion is PO4 (with a 3- valence). pediatric patients 12 years and older as a source of phosphorus in intravenous fluids to correct hypophosphatemia when oral or enteral replacement is not possible, insufficient, or contraindicated. The solution is administered after dilution or admixing by the intravenous route. Subscribe to Drugs.com newsletters for the latest medication news, new drug approvals, alerts and updates. Synonyms. Supplements containing a form of inorganic phosphate may be required to prevent or minimize deficiency symptoms such as fatigue, stiff joints and numbness.


Common Legal Phrases, Best Restaurants Near Exeter, Baked Salmon Patties Without Breadcrumbs, Parasite Eve Wiki, Dark Souls 3 The Fire Fades Edition Steam, Mobile Homes For Sale In Topsham Maine, Zucchini Tart Ricotta, Tetris Effect Hydelic, Tetris Effect Soundtrack Flac, Avocado Salsa For Fish,